Management holds a conference call to provide an overview of the Company’s Immuno-STAT (Selective Targeting and Alteration of T cells) platform and development strategy, as well as updates on key programs and anticipated milestones, on August 23 at 8:30 am. Webcast Link: https://edge.media-server.com/m6/p/sre5hjuj
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.